Background and aims: Direct-acting antiviral agents (DAAs) for hepatitis C virus (HCV) infection have resulted in high rates of sustained virologic response (SVR) following 8 to 24 weeks of treatment. However, difficult-to-cure/cirrhotic patients typically require a longer treatment duration and less is known regarding the longterm durability of SVR or effect on liver disease progression; to assess this, the IMPACT study followed patients for a 3-year period after end of treatment. Methods: The Phase II, open-label, nonrandomized IMPACT study assessed the efficacy, safety, and pharmacokinetics of the combination of three DAAs (simeprevir, sofosbuvir, and daclatasvir) in HCV genotype 1/4-infected, treatment-naïve/-experienced cirrhotic patients with portal hypertension or decompensated liver disease. Patients from a single site in the United States were assigned to one of two groups by Child-Pugh (CP) score: CP A, CP score less than 7 and evidence of portal hypertension; CP B, CP score of 7 to 9. All patients received simeprevir 150 mg, daclatasvir 60 mg, and sofosbuvir 400 mg once-daily for 12 weeks between September 2014 and August 2015. All 40 patients included in the study (male, 63%; median age, 58.5 years) achieved SVR 12 and 24 weeks after end of treatment, and the combination was well tolerated. Results: All patients who reached the 3-year follow-up timepoint maintained SVR (CP A, 15/15; CP B, 18/18). CP scores and Model for End-stage Liver Disease scores remained relatively stable, and mean FibroScan and FibroTest scores declined. No new safety signals were identified.
| INTRODUCTION
In 2015, it was estimated that 71 million individuals worldwide had chronic hepatitis C virus (HCV) infection. 1 HCV infection is a leading cause of chronic liver disease, 2,3 with many patients developing liver cirrhosis or hepatocellular carcinoma. 4 Furthermore, patients who develop decompensated liver disease have decreased survival rates compared with those patients with compensated cirrhosis. 5 Current guidelines recommend the use of interferon-free combinations of direct-acting antiviral agents (DAAs) for the treatment of HCV infection. 6, 7 Favorable efficacy and tolerability have been demonstrated with these regimens following treatment durations of 8 to 24 weeks (dependent on HCV genotype [GT] and patient characteristics). 6 However, difficult-to-cure patients, including those with cirrhosis, typically require a longer treatment duration. 6 In addition, the presence of decompensated liver disease may result in impaired hepatic metabolism, affecting the plasma concentrations of the DAAs used. 8 Simeprevir, sofosbuvir, and daclatasvir are DAAs with nonoverlapping resistance profiles, different mechanisms of action, and different metabolic pathways that target chronic HCV infection. 9, 10 Simeprevir is an HCV NS3/4A protease inhibitor with antiviral activity against GTs 1, 2, 4, 5, and 6 11, 12 ; sofosbuvir is a pangenotypic nucleotide HCV NS5B polymerase inhibitor 13 ; and daclatasvir is a pangenotypic HCV NS5A replication complex inhibitor. 10, 14 The Phase II IMPACT study (ClinicalTrials.gov number: NCT02262728) was the first to assess the combination of simeprevir, sofosbuvir, and daclatasvir for 12 weeks in HCV GT1-or 4-infected treatment-naïve or -experienced patients with Child-Pugh (CP A) cirrhosis with portal hypertension, or decompensated liver disease (CP B), with a planned 5-year follow-up period. 10 As published previously, all 40 patients (100%) achieved sustained virologic response (SVR)12 and SVR24, and the 3-DAA combination was well tolerated. During the long-term follow-up phase, the study sponsor decided to cease their HCV clinical development program. 15 Therefore, this manuscript presents the results of the final analysis for the long-term follow-up period of the study (reduced to up to 3 years after the end of treatment [EOT]).
| METHODS
The study design, methodology, key inclusion and exclusion criteria, and procedures of this trial have been reported previously. 10 The study included both treatment-naïve and interferon-based (± ribavirin) HCV treatment-experienced patients of at least 18 years of age with chronic HCV GT1-or 4-infection and cirrhosis (defined as a FibroScan ® score >14.5 kPa at screening). Liver disease was classified by CP score; CP A, score less than 7 with documented portal hypertension; CP B, score 7 to 9.
| Patients and study design

| Procedures
During the long-term follow-up period of the study, efficacy 
| Detection of HCV RNA
Blood samples were collected at predefined time points during the long-term follow-up period, at the 1-, 1.5-, 2-, 2.5-, and 3-year followup visits, and plasma was subsequently isolated. RNA extraction and quantification of HCV RNA was performed in a central laboratory using the COBAS ® AmpliPrep/COBAS ® TaqMan ® HCV Quantitative Test v2.0 (Roche; lower limit of quantification: 15 IU/mL). Further details of this methodology have been reported previously 10 (see appendix S1 of the previous IMPACT article).
| Assessment of liver disease status
Liver disease status was monitored by the assessment of CP, MELD, FibroTest, and FibroScan scores, which were assessed at screening or baseline and during follow-up.
| Safety
During the long-term follow-up phase, reporting of adverse events (AEs) was limited to all serious AEs (SAEs) only.
| Objectives
The objectives of the long-term follow-up phase were to assess the durability of SVR in the IMPACT study and the effect of treatment on liver disease progression.
| Statistics
Since this was an exploratory analysis within an exploratory study, no formal sample size calculation was performed; however, it was considered that a total sample size of 40 patients would be sufficient to explore the primary and secondary objectives, as reported previously. 10 All efficacy analyses were performed on the intentto-treat (ITT) population (all enrolled patients who had taken at least one dose of any study drug). The endpoints were analyzed overall and by CP class using descriptive statistics, using SAS version 9.4.
| Ethics
The study was approved by IntegReview IRB, a regional Institutional Review Board in Austin, Texas, and met the principles of the Declaration of Helsinki. All patients provided written informed consent. 
| RESULTS
| Patient disposition
| Baseline demographics and disease characteristics
| Efficacy
| Safety
During the treatment phase, there were no deaths or AEs that led to treatment discontinuation. 10 During the 3-year follow-up period, Other SAEs reported in two patients or more within the CP B group included: abdominal pain (n = 2) and ascites (n = 2). One patient in the CP B group died during the 3-year follow-up period (due to an upper GI bleed). However, no SAEs or deaths were considered to be related to study treatment (Table 1 ).
| DISCUSSION
The Phase II IMPACT study assessed the combination of simeprevir, sofosbuvir, and daclatasvir for 12 weeks in HCV GT1-or 4-infected, treatment-naïve, or -experienced patients with portal hypertension or decompensated liver disease. These three DAAs have different mechanisms of action and metabolic pathways, with non-overlapping resistance profiles. 9, 10 This was the first clinical study using this combination of treatment to evaluate shorter than 24 weeks of treatment in patients with decompensated liver disease. The 3-year follow-up period allowed an investigation into the effects of longterm DAA treatment on disease progression and the durability of SVR in patients with advanced liver disease.
During the long-term follow-up phase of this study, the sponsor decided not to continue their HCV clinical development program. This decision was not driven by a safety concern. Irrespective of this decision, the 3-year follow-up data analyzed here, provides insight into durability of response in patients with decompensated liver disease and, therefore, it was considered to be of significant relevance to the field. months, late relapse in patients who achieved SVR with daclatasvir and asunaprevir was rare (4 of 413 patients) and comparable with that seen following interferon therapy. 17 The results of the IMPACT study also provide insight into the long-term effects of such treatment regimens on liver function. The CP scores for the majority of patients in the CP A and CP B groups HCC. In the CP B group, one patient died due to an upper GI bleed, which was not considered to be related to the study treatment.
In this study, four patients developed de novo HCC following SVR. A recent review article summarizing the results of 11 studies examining the incidence of HCC following DAA treatment reported a de novo incidence rate of 0% to 7.4%, with the authors commenting that their review does not suggest that there is a higher rate of de novo HCC occurrence or recurrence after DAA therapy. 19 Furthermore, it has also been suggested that SVR is associated with a significant decrease in de novo or recurrent HCC, 20 dissipating concerns of DAA treatment being associated with subsequent occurrence of HCC.
When compared with interferon-based regimens, evidence has indicated that there may be a mild increased risk of de novo HCC with DAA treatment. 21 However, interferon-based regimens can only be given with caution to patients with cirrhosis and only if they have sufficient liver function and minimal portal hypertension. 21 This was an exploratory study, and as such, there were several 
